The Delaware Court of Chancery has denied a motion by shareholders of Pennsylvania-based BioClinica Inc. to expedite their lawsuit against the company, holding that the company did not adopt preclusive deal protection measures when it agreed to a $123 million buyout from JLL Partners Inc.
Font Size: 
Poison Pill Not Preclusive in $123 Mil. BioClinica Merger
The Legal Intelligencer
March 11, 2013
This article requires premium access
This article requires premium access to The Legal Intelligencer. Please sign in or subscribe to read the full text.
